The following lawsuit, filed in the U.S. District Court for the Western District of Oklahoma, alleges that users of Reglan risk developing movement disorders such as tardive dyskinesia. Further, the lawyers allege that after showing signs of tardive dyskinesia, Susan Schrock in fact developed that movement disorder:
3.10 Upon information and belief, in prescribing the Reglan/metoclopramide to Mrs. Schrock on a long-term basis, her prescribing doctor relied upon information published in the package inserts and/or the Physicians' Desk Reference (hereinafter referred to as “PDR”) or otherwise disseminated by the Reference Listed Drug Company (hereinafter referred to as “RLD”) and/or the New Drug Application Holder (hereinafter referred to as “NDA Holder”).
3.11 Mrs. Schrock ingested the Reglan/metoclopramide as prescribed.
3.12 Mrs. Schrock used the pharmaceutical drugs Reglan/metoclopramide without substantial change in the condition of the drugs between the time of design and manufacture of the drugs and the time she used the drugs as directed.
3.13 Mrs. Schrock's long-term ingestion of the Reglan/metoclopramide caused her injuries.
3.14 Mrs. Schrock was not aware of information different from or contrary to the inaccurate, misleading, materially incomplete, false and/or otherwise inadequate information disseminated in the PDR, RLD, or by the NDA Holders.
3.15 In June of 2006, Mrs. Schrock was exhibiting abnormal movements which have since been linked to her use of Reglan/metoclopramide.
3.16 Mrs. Schrock's use of Reglan/metoclopramide, as prescribed, resulted in overexposure to the drugs which have caused her to suffer serious, permanent and disabling injuries, including but not limited to, injuries of or associated with the central nervous and extrapyramidal motor systems, specifically Tardive Dystonia, a severe and often permanent disfiguring neurological movement disorder.
3.17 Mrs. Schrock's serious and permanent injuries, as described above, came about as a foreseeable and proximate result of Defendants' dissemination of inaccurate, misleading, materially incomplete, false and otherwise inadequate information concerning the potential effects of exposure to and long-term ingestion of Reglan/metoclopramide to the medical community, Mrs. Schrock, and other foreseeable users of the drug.
